Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial

Summary Background No standard chemotherapy regimen exists for primary CNS lymphoma, reflecting an absence of randomised studies. We prospectively tested two promising methotrexate-based regimens, one more intensive and a milder regimen, for primary CNS lymphoma in the elderly population, who accoun...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet. Haematology 2015-06, Vol.2 (6), p.e251-e259
Hauptverfasser: Omuro, Antonio, MD, Chinot, Olivier, MD, Taillandier, Luc, MD, Ghesquieres, Hervé, MD, Soussain, Carole, MD, Delwail, Vincent, MD, Lamy, Thierry, MD, Gressin, Rémy, MD, Choquet, Sylvain, MD, Soubeyran, Pierre, MD, Huchet, Aymeri, MD, Benouaich-Amiel, Alexandra, MD, Lebouvier-Sadot, Sophie, MD, Gyan, Emmanuel, MD, Touitou, Valérie, MD, Barrié, Maryline, MD, del Rio, Monica Sierra, MD, Gonzalez-Aguilar, Alberto, MD, Houillier, Caroline, MD, Delgadillo, Daniel, PhD, Lacomblez, Lucette, PhD, Tanguy, Marie Laure, PhD, Hoang-Xuan, Khê, Dr
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background No standard chemotherapy regimen exists for primary CNS lymphoma, reflecting an absence of randomised studies. We prospectively tested two promising methotrexate-based regimens, one more intensive and a milder regimen, for primary CNS lymphoma in the elderly population, who account for most patients. Methods In this open-label, randomised phase 2 trial, done in 13 French institutions, we enrolled immunocompetent patients who had neuroimaging and histologically confirmed newly diagnosed primary CNS lymphoma, were aged 60 years and older, and had a Karnofsky performance scale score of 40 or more. Participants were stratified by Karnofsky performance scale score (
ISSN:2352-3026
2352-3026
DOI:10.1016/S2352-3026(15)00074-5